International Conference of Natural and Medical Sciences, Young Scientists, PhD Students and Students

Conference combined with training workshops will be held on December 1st, 2017 to December 3rd, 2017 in Lublin. Presentations of the participants’ work will be shown during the Conference. Also, interesting and free trainings as well as integration party will be held. Read full text »

Noninvasive imaging of atherosclerotic plaque instability by MRI

iStock_000015911522_DoubleAtherosclerosis is a significant risk factor of coronary and cerebrovascular occlusive accidents, manifested as acute myocardial infarction or ischemic stroke, which remain a leading causes of morbidity and mortality worldwide. Due to its multifactorial etiology and clinical implications, atherosclerosis has become an subject of many studies regarding a pathogenesis and natural course of the disease. According to the latest news provided by scientists from Boston University School of Medicine, the development and identification of atherosclerotic plaques at the highest risk for thrombosis can be successfully evaluated by using Magnetic Resonance Imaging (MRI). Read full text »

Tuberculosis – comparison of diagnostic methods

Tuberculosis is a common human and animal infectious disease occurring worldwide caused by Gramm positive acid-fast bacteria. The most dangerous for people are typical strains Mycobacterium tuberculosis and Mycobacterium bovis. Every year around 8-9 mln of new cases are reported and 2 million people dies because of the infection and its complication. This places tuberculosis on the top of the leading infectious diseases, with regard to morbidity and mortality worldwide. Despite the fact that BCG vaccines are available, the situation is very serious because there are many problems i.a. difficulties in detecting myobacteria and its multidrugresistance . (1) Read full text »

A vaccine for breast cancer

A new vaccine (Neuvax, nelipepimut-S or E75), which can prevent recurrence of early-stage, HER2 medium or low expression breast cancer, is being tested. Currently, since 2011 the vaccine is in a third phase of clinical trials but the preliminary results will be known in 2015. Vaccine is directed against E75 peptide isolated from the protein receptor HER2/neu. The results of the first and second phase of trials indicate reduced recurrence of the cancer than in the control group, lower mortality rate and the absence of bone metastasis in case of recurrence. In the article the way of action, patients’ criteria selection, results of the first and second phase of clinical trials, toxicity as well as perspective of spreading the vaccine, will be presented. Read full text »